stockrow
Friday 6 November 2026
Export RPRX’s income statement to Excel — free account
Royalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
67.28
0.29
−0.43%
Follow RPRX
Alert me
Royalty Pharma PLC (RPRX) Net income
Royalty Pharma PLC's net income for fiscal 2025 was $1.3B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $1.3B. Over the past ten years it has ranged from $0.00 (fiscal 2017) to $2.5B (fiscal 2019); the current reading is higher than 44% of that period. Royalty Pharma PLC ranks 5th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $1.3B | (0.50%) |
| FY2024 | $1.3B | (21.72%) |
| FY2023 | $1.7B | 638.96% |
| FY2022 | $230.1M | (81.46%) |
| FY2021 | $1.2B | (27.07%) |
| FY2020 | $1.7B | (30.85%) |
| FY2019 | $2.5B | 62.16% |
| FY2018 | $1.5B | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $81.5M | (82.60%) |
| Mar 2026 | $468.3M | 31.56% |
| Dec 2025 | $355.9M | (19.33%) |
| Sep 2025 | $441.2M | 376.29% |
| 26 more quarters | Free account |
Against its own ten years
Low $0.00
High $2.5B
Ten-year median
$1.3B
Current reading's percentile
44
Net income against peers
| Company | Net income |
|---|---|
| ARGX argenex SE compare | $1.6B |
| RPRX Royalty Pharma PLC | $1.3B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $915.6M |
| GMAB Genmab A/S Sponsored ADR compare | $906.0M |
| INCY Incyte Corporation compare | $403.4M |
| ROIV Roivant Sciences Ltd. compare | −$414.6M |
| INSM Insmed, Inc. compare | −$605.6M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.6B |
| RVMD Revolution Medicines, Inc. compare | −$1.9B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on RPRX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement